Charles-Schoeman, C., Buch, M. H., Dougados, M., Bhatt, D. L., Giles, J. T., Ytterberg, S. R., Koch, G. G., Vranic, I., Wu, J., Wang, C., Kwok, K., Menon, S., Rivas, J. L., Yndestad, A., Connell, C. A., & Szekanecz, Z. (2022). Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Annals of the Rheumatic Diseases, 82(1), 119–129. https://doi.org/10.1136/ard-2022-222259